Data Sharing Statement

Butler. Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction. *JAMA Cardiol*. Published May 24, 2023. doi:10.1001/jamacardio.2023.1090

Data

Data available: Yes

Data types: Deidentified participant data

How to access data: To ensure independent interpretation of clinical study results and enable authors to fulfil their role and obligations under the ICMJE criteria, Boehringer Ingelheim grants all external authors access to relevant clinical study data pertinent to the development of the publication. In adherence with the Boehringer Ingelheim Policy on Transparency and Publication of Clinical Study Data, scientific and medical researchers can request access to clinical study data when it becomes available on Vivli - Center for Global Clinical Research Data (https://vivli.org/), and earliest after publication of the primary manuscript in a peerreviewed journal, regulatory activities are complete and other criteria are met. Please visit https://www.mystudywindow.com/msw/datasharing for further information.

When available: With publication

Supporting Documents Document types: None

Additional Information

Who can access the data: Anyone requesting the data.

Types of analyses: For any purpose.

Mechanisms of data availability: With a signed data access agreement